SEC Tracker
Get the app

Sarepta Therapeutics SRPT

Sarepta Therapeutics reported a net loss of $28.46 million for the three months ended Sep 30, 2026.

Form
10-Q
Filed
Importance
Notable
  1. Revenue was $381.35 million for the three months ended Sep 30, 2026.
  2. Diluted EPS was -$0.27 for the three months ended Sep 30, 2026.
  3. Cash and equivalents were $472.76 million as of Sep 30, 2026.

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Sarepta Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

From the filing's financial data, not stated in its text

From this 10-Q's financial data (XBRL) for the quarter ended September 30, 2026

  • The company reported revenue of $323.8 million for the quarter.
  • For the quarter ended September 30, 2026, Sarepta Therapeutics, Inc. reported a net income of -$28.5 million.
  • The operating margin was -2.8%, and the net margin was -8.8%.
  • Revenue decreased by 12.5% compared to the same period a year earlier.
  • In its 10-Q for the quarter ended September 30, 2026, Sarepta Therapeutics, Inc. provided financial data.
  • The filing also includes information on the company's performance relative to the previous year.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Supernus Pharmaceuticals SUPN public float $1.7B, Jun 30, 2025
  2. Ocular Therapeutix OCUL public float $1.6B, Jun 30, 2025
  3. Ligand Pharmaceuticals LGND public float $1.6B, Jun 30, 2025
  4. Amicus Therapeutics FOLD public float $1.7B, Jun 30, 2025
  5. Apellis Pharmaceuticals APLS public float $1.8B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.